ARC Desk

Pharmaceutical Contract Manufacturing Market Garner USD 150.82 billion by 2025

Lehdistötiedote   •   Marras 08, 2019 14:39 EET

​The increasing subcontracting volume by big pharmaceutical companies, expansion in the service offering of complementary metal–oxide–semiconductor (CMOS), and advent of contract development & manufacturing organization (CDMO) model into the market, and growing investment in R&D are the major trends for the demand of the market.

The global pharmaceutical contract manufacturing market is expected to grow from USD 92.83 billion in 2017 to USD 150.82 billion by 2025 at a CAGR of 5.35% during the forecast period from 2018-2025, according to the new report.

The demand for generic medicines and biologics, capital-intensive nature of the business, and complex manufacturing requirements is growing day-by-day. This has increased the focus of many pharmaceutical businesses to gain profitability in contracting with a CMO (contract manufacturing outsourcing). Pharmaceutical companies are relying on contract manufacturing and packaging services to meet their fundamental needs and specified competencies, along with accomplishing stringent regulations. For instance, Recipharm, a leading contract development and manufacturing organization (CDMO) signed a contract with Kancera, a development company focused on cancer therapy for the development and manufacture of the pharmaceutical candidate, named as KAND567.

The increasing subcontracting volume by big pharmaceutical companies, expansion in the service offering of complementary metal–oxide–semiconductor (CMOS), and advent of contract development & manufacturing organization (CDMO) model into the market are the key driving factors for the pharmaceutical contract manufacturing market. In addition, growing investment in R&D will lead to the growth of pharmaceutical contract manufacturing market in a couple of years. The increasing lead time and logistics costs and stringent regulatory requirements may limit the growth of market. Increasing demand for next-generation biological therapies is expected to boost the pharmaceutical contract manufacturing market over the forecast period.

Key players operating in the global pharmaceutical contract manufacturing market are Jubilant Life Sciences Ltd, Catalent Inc., Recipharm AB, Patheon Inc., Boehringer Ingelheim, Pfizer Centresource, Baxter Biopharma Solutions, Aenova, Famar, Lonza, Aesica Pharmaceuticals, Mylan, Vetter Pharma International, Fareva Group. The Patheon, Catalent, Lonza, Evonik Industries, Boehringer Ingelheim are the top leading players of the market. In order to enhance their market position in the global pharmaceutical contract manufacturing market, the key players are now focusing on adopting strategies such as product innovations, mergers & acquisitions, recent developments, joint venture, collaborations, and partnership..

  • For instance in 2018, Kangstem Biotech has selected Orgenesis subsidiary, MaSTherCell, as its contract manufacturing partner for the European clinical trial of Furestem-AD. Through this partnership, Kangstem gains access to MaSTherCell’s cell therapy manufacturing expertise, capabilities, and new commercial Agility-by-Design facility.
  • For instance in 2017, Catalent Inc. acquired Cook Pharmica LLC. This acquisition strengthened Catalent’s position in biologics development and analytical services and also complements capabilities and expertise in biologic drug development programs.

For More information, Visit@ sales@acumenresearchandconsulting.com